Periodontitis - Pipeline Review, H1 2020

February 2020 | 58 pages | ID: PFE5D69AC8BEN
Global Markets Direct

Abstracts

Periodontitis - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Periodontitis - Pipeline Review, H1 2020, provides an overview of the Periodontitis (Mouth And Dental Disorders) pipeline landscape.

Periodontitis is a gum infection that damages the soft tissue and destroys the bone that supports teeth. Signs and symptoms of periodontitis include swollen gums, bright red or purplish gums, bad breath, bright red or purplish gums and spaces developing between teeth. Risk factors include gingivitis, heredity, diabetes, age, substance abuse and weakened immune system.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Periodontitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Periodontitis (Mouth And Dental Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Periodontitis (Mouth And Dental Disorders) pipeline guide also reviews of key players involved in therapeutic development for Periodontitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical, Discovery and Unknown stages are 5, 4, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Periodontitis (Mouth And Dental Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Periodontitis (Mouth And Dental Disorders).
• The pipeline guide reviews pipeline therapeutics for Periodontitis (Mouth And Dental Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Periodontitis (Mouth And Dental Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Periodontitis (Mouth And Dental Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Periodontitis (Mouth And Dental Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Periodontitis (Mouth And Dental Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Periodontitis (Mouth And Dental Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Periodontitis - Overview
Periodontitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Periodontitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Periodontitis - Companies Involved in Therapeutics Development
Amyndas Pharmaceuticals LLC
Cellatoz Therapeutics Inc
Cells for Cells SA
Denteric Pty Ltd
Geistlich Pharma AG
GEXVal Inc
GlycoMira Therapeutics Inc
Guangzhou Saliai Stemcell Science and Technology Co Ltd
KIMS Pharmaceutical Co Ltd
MetiMedi Pharmaceuticals Co Ltd
Noveome Biotherapeutics Inc
PerioTrap Pharmaceuticals GmbH
TGV Laboratories Inc
Periodontitis - Drug Profiles
AMY-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLZ-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Protein to Activate Del-1 for Multiple Sclerosis and Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GM-0111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXV-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIMS-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
METI-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myc-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PODOH-CRC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ranokure - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Glutaminyl Cyclase for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ST-266 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Stem Cell Therapy for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taurolidine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Periodontitis - Dormant Projects
Periodontitis - Discontinued Products
Periodontitis - Product Development Milestones
Featured News & Press Releases
Aug 26, 2019: Amyndas Pharmaceuticals initiates phase 2a study of AMY-101 in adults with periodontal inflammation and gingivitis
Dec 13, 2017: Amyndas Pharmaceuticals Announces Positive Results from a Phase I Trial of its new complement C3 inhibitor AMY-101
Jun 15, 2016: Noveome Initiates Phase 2 Clinical Trial of ST266 to Treat Patients with Periodontitis
Mar 07, 2016: Penn Team Reverses Signs of Naturally Occurring Chronic Periodontitis
May 20, 2014: Penn Team Identifies Promising New Target for Gum Disease Treatment
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Periodontitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Periodontitis - Pipeline by Amyndas Pharmaceuticals LLC, H1 2020
Periodontitis - Pipeline by Cellatoz Therapeutics Inc, H1 2020
Periodontitis - Pipeline by Cells for Cells SA, H1 2020
Periodontitis - Pipeline by Denteric Pty Ltd, H1 2020
Periodontitis - Pipeline by Geistlich Pharma AG, H1 2020
Periodontitis - Pipeline by GEXVal Inc, H1 2020
Periodontitis - Pipeline by GlycoMira Therapeutics Inc, H1 2020
Periodontitis - Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, H1 2020
Periodontitis - Pipeline by KIMS Pharmaceutical Co Ltd, H1 2020
Periodontitis - Pipeline by MetiMedi Pharmaceuticals Co Ltd, H1 2020
Periodontitis - Pipeline by Noveome Biotherapeutics Inc, H1 2020
Periodontitis - Pipeline by PerioTrap Pharmaceuticals GmbH, H1 2020
Periodontitis - Pipeline by TGV Laboratories Inc, H1 2020
Periodontitis - Dormant Projects, H1 2020
Periodontitis - Dormant Projects, H1 2020 (Contd..1), H1 2020
Periodontitis - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Periodontitis, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Targets, H1 2020
Number of Products by Stage and Targets, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Amyndas Pharmaceuticals LLC
Cellatoz Therapeutics Inc
Cells for Cells SA
Denteric Pty Ltd
Geistlich Pharma AG
GEXVal Inc
GlycoMira Therapeutics Inc
Guangzhou Saliai Stemcell Science and Technology Co Ltd
KIMS Pharmaceutical Co Ltd
MetiMedi Pharmaceuticals Co Ltd
Noveome Biotherapeutics Inc
PerioTrap Pharmaceuticals GmbH
TGV Laboratories Inc